公开(公告)号：US10766965B2

公开(公告)日：2020-09-08

申请号：US15160476

申请日：2016-05-20

申请人： Janssen Biotech, Inc. ,  Tufts Medical Center, Inc.

发明人： Chakra Chaulagain ,  Raymond Comenzo ,  Parul Doshi ,  Xun Ma ,  Amy Sasser

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K9/00 ,  A61K31/573 ,  A61K31/664 ,  A61K31/69 ,  A61K38/05 ,  A61K38/47 ,  A61K45/06 ,  A61K39/00

摘要： The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.

公开(公告)号：US20200263172A1

公开(公告)日：2020-08-20

申请号：US16836644

申请日：2020-03-31

申请人： WUHAN NEUROPHTH BIOLOGICAL TECHNOLOGY LIMITED COMPANY

发明人： Bin LI

IPC分类号： C12N15/11 ,  C12N9/02 ,  C12N15/86 ,  C12N7/00 ,  A61K35/76 ,  A61K31/573 ,  A61K31/664 ,  A61K9/00

摘要： Disclosed herein is a recombinant nucleic acid, comprising: a mitochondrial targeting sequence; a mitochondrial protein coding sequence, wherein said mitochondrial protein coding sequence encodes a polypeptide comprising a mitochondrial protein; and a 3′UTR nucleic acid sequence. Also disclosed is a pharmaceutical composition comprising the recombinant nucleic acid and a method of treating Leber's hereditary optic neuropathy (LHON) using the pharmaceutical composition.

公开(公告)号：US10583198B2

公开(公告)日：2020-03-10

申请号：US15557369

申请日：2016-03-11

申请人： VIVENTIA BIO INC.

发明人： Glen MacDonald ,  Stephen Hurly

IPC分类号： A61K39/395 ,  A61K47/68 ,  C07K16/30 ,  A61P35/00 ,  A61K33/24 ,  A61K31/282 ,  A61K31/337 ,  A61K31/513 ,  A61K38/14 ,  A61K31/519 ,  A61K31/664 ,  C07K16/28 ,  A61K38/16 ,  A61K38/45 ,  A61K31/555 ,  A61K31/675 ,  A61K45/06 ,  A61K39/00

摘要： The present disclosure provides methods for treatment of bladder cancer. The methods include administering an immunoconjugate to a subject in a dosing regimen that includes an induction phase with twice weekly followed by once weekly dosing, and optionally a maintenance phase. The immunoconjugates useful in the methods provided include immunoconjugates having a binding protein that specifically binds to Ep-CAM and a toxin molecule.

公开(公告)号：US10517822B2

公开(公告)日：2019-12-31

申请号：US15034799

申请日：2014-11-06

申请人： The University of Chicago ,  The University of North Carolina at Chapel Hill

发明人： Wenbin Lin ,  Chunbai He ,  Demin Liu

IPC分类号： A61K9/127 ,  A61K31/663 ,  A61K9/51 ,  C12N15/11 ,  A61K45/06 ,  A61K31/664 ,  A61K31/713 ,  C12N15/113

摘要： Nanoscale coordination polymer nanoparticles for the co-delivery of multiple therapeutic agents are described. The multiple therapeutic agents can include a combination of different chemotherapeutic agents, a combination of one or more chemotherapeutic agents and one or more nucleic acids, such as small interfering RNA (siRNA) or microRNA, a combination of one or more chemotherapeutic agents and a photosensitizer (i.e., for use in photodynamic therapy), or a plurality of different siRNAs. Pharmaceutical formulations including the nanoparticles, methods of using the nanoparticles to treat cancer, and methods of making the nanoparticles are also described.

公开(公告)号：US10478439B2

公开(公告)日：2019-11-19

申请号：US15965114

申请日：2018-04-27

申请人： Pharmacyclics LLC

发明人： Lee Honigberg ,  David J. Loury

IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K9/48 ,  A61K31/519 ,  A61K31/195 ,  A61K31/436 ,  A61K31/454 ,  A61K31/475 ,  A61K31/573 ,  A61K31/606 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7076 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4745 ,  A61K31/7032 ,  A61K39/395 ,  C07D487/04 ,  A61K31/337 ,  A61K31/437 ,  A61K31/664

摘要： Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：US20190151362A1

公开(公告)日：2019-05-23

申请号：US16164995

申请日：2018-10-19

申请人： CARsgen Therapeutics Co., LTD.

发明人： Zonghai Li ,  Huiping Gao ,  Peng Wang ,  Hua Jiang ,  Huamao Wang

IPC分类号： A61K35/17 ,  A61P35/00 ,  A61K9/00 ,  A61K31/519 ,  A61K31/7048 ,  A61K31/664 ,  A61K31/7076 ,  A61K38/20

摘要： Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

公开(公告)号：US20190125799A1

公开(公告)日：2019-05-02

申请号：US16175663

申请日：2018-10-30

申请人： Allogene Therapeutics, Inc. ,  Les Laboratoires Servier

发明人： Cyril Alkis KONTO ,  Amina ZINAI

IPC分类号： A61K35/17 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  A61K31/7076 ,  A61K31/664 ,  A61K39/395 ,  A61P35/00 ,  C12N5/0783 ,  A61K38/17

摘要： The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.

公开(公告)号：US20190038643A1

公开(公告)日：2019-02-07

申请号：US15665862

申请日：2017-08-01

申请人： University of South Carolina

发明人： Qian Wang

IPC分类号： A61K31/664 ,  A61L15/64 ,  A61L15/44 ,  A61L15/42 ,  A61L15/26 ,  A61L15/28

CPC分类号： A61K31/664 ,  A61L15/26 ,  A61L15/28 ,  A61L15/425 ,  A61L15/44 ,  A61L15/64 ,  A61L2300/10 ,  A61L2300/216 ,  A61L2300/41 ,  A61L2300/412 ,  A61L2400/12 ,  A61L2430/34 ,  C08L5/04 ,  C08L5/08 ,  C08L67/04

摘要： A dressing for wound healing is provided, wherein the dressing includes a hydrogen sulfide (H2S) donor compound. The dressing facilitates the delivery of H2S to a wound site in a controlled manner, which results in an improved wound healing process by stimulating angiogenesis and anti-inflammatory action. In some embodiments, the wound dressing can include an electrospun nanofiber dressing, a sponge dressing, or a hydrogel dressing.

公开(公告)号：US20190030117A1

公开(公告)日：2019-01-31

申请号：US16162218

申请日：2018-10-16

申请人： PIN Pharma, Inc.

发明人： Joshua Goldberg ,  Colin Bier

IPC分类号： A61K38/16 ,  A61K39/21 ,  A61K31/664 ,  A61K39/39 ,  C12N15/63 ,  A61K39/00 ,  C07K14/005

摘要： Disclosed herein are compositions comprising a Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) derivative polypeptide with increased immunostimulatory properties relative to the native Tat polypeptide, pharmaceutical compositions comprising the Tat derivative polypeptide, and methods of treating cancer using the Tat derivative polypeptide.

公开(公告)号：US20190000797A1

公开(公告)日：2019-01-03

申请号：US15750712

申请日：2016-08-18

申请人： Eisai R&D Management Co., Ltd.

发明人： Kiyoshi Okamoto ,  Junji Matsui ,  Corina Dutcus

IPC分类号： A61K31/357 ,  A61K31/47 ,  A61P35/00 ,  A61K31/664

摘要： A novel tumor therapeutic agent for a combination therapy is disclosed. More specifically, a tumor therapeutic agent used for a combination therapy of lenvatinib, ifosfamide, and etoposide is disclosed.